Friday, 26 February 2016

Research Report - Parkinson’s Disease Market 2022 Published By Radiant Insights, Inc

Parkinson’s disease (PD) is the second common neurodegenerative disease after Alzheimer’s. It usually affects people above the age of 50 with symptoms of bradykinesia and rigidity being the most common. It is caused by the loss of dopamine-producing neurons within the basal ganglia. As the disease progresses, it leads to disability in patients restricting major motor functions. 

PD is difficult to diagnose without a medical history or neurological examination. Patients in the advanced stages suffer from shaking and difficulty of swallowing and chewing. Other symptoms include depression, impaired balance, and urinary problems. Anticholinergics can control the tremors mixed with levodopa. Carbidopa delays the conversion of levodopa before it changes to dopamine. Other dopamine agonists include pramipexole, ropinirole, and bromocriptine mimic the same role as dopamine.

The market currently offers drugs which offer symptomatic relief. The global geriatric population is the major driver of Parkinson’s disease drug market. But the need for a disease-modifying drug will drive the market demand over the years ahead. The market is projected to reach about USD 5 billion by 2022.

For Further Inquiries:

Levodopa is the current reigning drug in the market among other dopamine agonists and Monoamine Oxidase B (MAO-B). Germany, Spain, Japan, Italy, United States, United Kingdom, and France are major sales regions for the market. Despite new drug therapies and dopaminenergic drugs, the market is at risk of being offset by generic competition. Launch of Xadago and Rytary are expected to improve drug sales for the market till 2022. Other drugs in the pipeline include Intec’s CD/LD-GR, Bial’s opicapone, Biotie’s tozadenant, and Acorda’s CVT-301. 

MAO-B inhibitors increase the dopamine levels by breaking the metabolism within the basal ganglia. They can be used to improve motor functions and restrict the use of levodopa. 

Alternatives to drugs is treatment with surgery. Three different types of surgery available are deep brain stimulation (DBS), transplantation or restorative, and ablative surgery. But less than 10% of patients qualify for surgery and chances of risk are higher than palliative care prescribed by doctors.

Key manufacturers that produce drugs to counter the effects of Parkinson’s disease are GlaxoSmithKline, AbbVie, Lundbeck, Novartis, and Merck.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: Radiant Insights 

No comments:

Post a Comment